UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

NOTICE OF ALLOWANCE AND FEE(S) DUE

001095

THOMAS HOXIE

ONE HEALTH PLAZA 430/2 EAST HANOVER, NJ 07936-1080

7590

02/18/2004

NOVARTIS, CORPORATE INTELLECTUAL PROPERTY

EXAMINER

PATEL, SUDHAKER B

ART UNIT

PAPER NUMBER

1624

DATE MAILED: 02/18/2004

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/077,150	02/15/2002	Bernhard Peter Neumann	4-30361B/C1	5272

TITLE OF INVENTION: BENZOTHIADIAZOLES AND DERIVATIVES

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1330	\$300	\$1630	05/18/2004

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED</u>. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

- A. Pay TOTAL FEE(S) DUE shown above, or
- B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.
 - □ Applicant claims SMALL ENTITY status. See 37 CFR 1.27.
- II. PART B FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.
- III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE Commissioner for Patents P.O. Box 1450

			or Fax		rginia 22313-1450	
INSTRUCTIONS: This for appropriate. All further corindicated unless corrected to maintenance fee notification	m should be used for tran respondence including the loelow or directed otherwise is.	smitting the ISSU Patent, advance or in Block 1, by (a			quired). Blocks I through 4 s s will be mailed to the current ss; and/or (b) indicating a sep	should be completed where correspondence address a arate "FEE ADDRESS" fo
CURRENT CORRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block 1)			use Block 1)	Note: A certificate of mailing can only be used for domestic mailings of th Fec(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must		
001095 75	90 02/18/2004			have its own certific	ate of mailing or transmission.	C,
THOMAS HOXI NOVARTIS, COR ONE HEALTH PL EAST HANOVER	PORATE INTELLEC [*] AZA 430/2	ΓUAL PROPE	RTY	I hereby certify that	Certificate of Mailing or Tran this Fee(s) Transmittal is bein e with sufficient postage for fi ail Stop ISSUE FEE address SPTO, on the date indicated be	g denosited with the Unite
						(Depositor's name)
						(Signature)
					· · · · · · · · · · · · · · · · · · ·	(Date)
APPLICATION NO.	FILING DATE		FIRST NAMED IN	VENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/077,150	02/15/2002		Bernhard Peter N	eumann	4-30361B/C1	5272
TITLE OF INVENTION: BI	ENZOTHIADIAZOLES AN	ID DERIVATIVES	S			
APPLN. TYPE	SMALL ENTITY	ISSUE FI	EE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	. \$1330)	\$300	\$1630	05/18/2004
EXAM	INER	ART UN	т	CLASS-SUBCLASS	7	
PATEL, SUI	OHAKER B	1624	•	514-183000	_	
1. Change of correspondence CFR 1.363). ☐ Change of corresponde Address form PTO/SB/12 ☐ "Fee Address" indicatic PTO/SB/47; Rev 03-02 o Number is required.	Correspondence	names of up agents OR, alt firm (having a agent) and the	For printing on the patent front page, list (1) the ames of up to 3 registered patent attorneys or gents OR, alternatively, (2) the name of a single rm (having as a member a registered attorney or gent) and the names of up to 2 registered patent ttorneys or agents. If no name is listed, no name vill be printed.			
3. ASSIGNEE NAME AND	RESIDENCE DATA TO B	E PRINTED ON T	HE PATENT (pri	nt or type)		
	an assignee is identified bel I to the USPTO or is being s	ow, no assignee da ubmitted under sep	ata will appear on parate cover. Com		assignee data is only approprio OT a substitute for filing an ass OUNTRY)	ate when an assignment has ignment.
Please check the appropriate	assignee category or category	ries (will not be pri	inted on the patent); ☐ individual ☐	corporation or other private gr	oup entity
4a. The following fee(s) are	enclosed:	4b	. Payment of Fee(s):		
☐ Issue Fee			A check in the	amount of the fee(s) is en	nclosed.	
☐ Publication Fee	☐ Payment by credit card. Form PTO-2038 is attached.					
☐ Advance Order - # of 0	Copies		The Director in Deposit Account		charge the required fee(s), or (enclose an extra c	credit any overpayment, to opy of this form).
Director for Patents is reques	ted to apply the Issue Fee ar	nd Publication Fee	(if any) or to re-ap	oply any previously paid	issue fee to the application ide	ntified above.
(Authorized Signature)		(Date)			***	
NOTE; The Issue Fee and other than the applicant; a interest as shown by the rec	Publication Fee (if require a registered attorney or age ords of the United States Pa	ed) will not be acc ent; or the assigned tent and Trademark	cepted from anyone or other party k Office.	ne in		
This collection of informat obtain or retain a benefit happlication. Confidentiality estimated to take 12 minut completed application for case. Any comments on suggestions for reducing the Patient and Trademark (22313-1450. DO NOT SI SEND TO: Commissioner	tion is required by 37 CFR by the public which is to five spoverned by 35 U.S.C. I les to complete, including gan to the USPTO. Time will the amount of time you rais burden, should be sent to the USPTO. The burden, should be sent price, U.S. Department of the public of Patents, Alexandria, Virgio Patents, Alexandria, Virgio programments, and programments of the public of Patents, Alexandria, Virgio programments, and programments of the public of	1.311. The inform le (and by the US 22 and 37 CFR 1.1 thering, preparing, I vary depending equire to complet o the Chief Inform of Commerce, A ITED FORMS TO inia 22313-1450.	nation is required PTO to process): 4. This collection, and submitting the upon the individute this form and/ nation Officer, U. lexandria, Virgin THIS ADDRES	to an is said and an is said an is		

· TRANSMIT THIS FORM WITH FEE(S)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS	
P.O. Box 1450	
Alexandria, Virginia 22313-1450	
www.uspto.gov	

TION NO. FILING DATE FIRST NAMED INVENTOR		CONFIRMATION NO.		
02/15/2002 Bernhard Peter Neumann		5272		
	EXAM	INER		
THOMAS HOXIE				
NOVARTIS, CORPORATE INTELLECTUAL PROPERTY				
	ART UNIT	PAPER NUMBER		
	1624			
	Bernhard Peter Neumann	Bernhard Peter Neumann 4-30361B/C1 EXAM PATEL, SUI L PROPERTY ART UNIT		

DATE MAILED: 02/18/2004

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 0 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 0 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system (http://pair.uspto.gov).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (703) 305-1383. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

Application No.	Applicant(s)					
10/077 150	NEUMANN, BERNHARD PETER					
	Art Unit					
Sudhaker B. Patel, D.Sc.Tech.	1624					
Th MAILING DATE of this communication app ars on the cover sh et with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.						
 4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 09/601,463. 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 						
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.						
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.						
6. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.						
on's Patent Drawing Review (PTO-	-948) attached					
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date						
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).						
7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.						
6. ☐ Interview Summary Paper No./Mail Da 3), 7. ☐ Examiner's Amendr						
	Examiner Sudhaker B. Patel, D.Sc.Tech. Ars on the cover sh et with the coordinate communication of the appropriate communication is subject to and MPEP 1308. This application is subject to and MPEP 1308. Seen received. Seen received in Application No. On this application is application in this communication to file a reply interest in this application. Seen received in Application in the communication to file a reply interest in this application. Seen received in Application in the communication to file a reply interest in the communication to file a reply interest in the communication in the communication to file a reply interest in the communication in the communication in the communication to file a reply interest in the communication in the communication is application. See a communication is subject to and the communication is subject					

Application/Control Number: 10/077,150

Art Unit: 1624

REASONS FOR ALLOWANCE

- 1. The following is an examiner's statement of reasons for allowance:
- 2. Applicants' communication paper dated 12/3/03 is acknowledged. Applicants have cancelled claims 4-9, amended claim 10, and presented new claims11, 12. Therefore the claims under consideration are the claims 1-3,10-12, which are renumbered as claims 1-6 respectively.
- 3. The rejection made under 35 U.S.C. 112 paragraph second are now withdrawn because applicants have presented the claims, which are now definite.
- 4. The rejections made under 35 U.S.C. 112 paragraph first are also withdrawn because applicants have cancelled claims 4-9, amended claim 10, and presented new claims which are enabled.
- 5. The closest prior art ref. of record Whitten et al (J.Of Med.Chem., 39/22,4354-4357(1996), also cited as Chemical Abstract DN 126:18845) teaches making of a compound with a core:""Benzo-thiadiazole-NH-1,2,5-triazine substituted by Me and NH-phenyl groups".
- 6. The reference does not teach or indicate to arrive at the instant compounds wherein sulfur has been replaced by O, N-CH3, -CH=CH-, or C-alk = C-alk.
- 7. Therefore, the instantly claimed compounds are deemed to be novel and patentably distinct.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably



Application/Control Number: 10/077,150

Art Unit: 1624

accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker B. Patel, D.Sc.Tech. whose telephone number is (571) 272-0671. The examiner can normally be reached on 6:30 to 5:00 pm (Monday-Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Mukund J. Shah can be reached on (571) 272 0674 or Sr. Examiner Mr. Richard Raymond at (571) 272 0673 or Mr. James Wilson at (571) 272-0661.

The fax phone numbers for the organization where this application or proceeding is assigned are 703 308 4556 for regular communications and 703 308 4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308 1235.

Sudhaker B.Patel, D.Sc.Tech.

February 10, 2004.

Richard L. Raymond

SUPERVISORY PATENT

EXAMINER

ART UNIT 1624